Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer.
Alexandra LearyCatherine GenestieFélix Blanc-DurandSébastien GouyAriane DunantAmandine MaulardFrançoise DruschBianca CheaibJudith MichelsEnrica BentivegnaAudrey LeFormalSoizick MesnagePhilippe MoricePatricia PautierAya S KhairallahPublished in: Cancer immunology, immunotherapy : CII (2020)
NACT has a significant impact on the balance of immune-reactive to immune-tolerant subpopulations and a high ratio of CD8+/FOXP3+, CD3+/FOXP3+, and CD68+/CD163+ post NACT was significantly associated with improved outcomes. Whether this could select patients for immunotherapy in the post-operative setting should be investigated.
Keyphrases
- neoadjuvant chemotherapy
- regulatory t cells
- end stage renal disease
- locally advanced
- ejection fraction
- newly diagnosed
- chronic kidney disease
- sentinel lymph node
- lymph node
- squamous cell carcinoma
- dendritic cells
- prognostic factors
- type diabetes
- adipose tissue
- nk cells
- radiation therapy
- early stage
- atomic force microscopy
- patient reported outcomes
- high resolution
- mass spectrometry
- rectal cancer
- patient reported
- high speed